Loading
The first checkpoint inhibitor trial in pancreatic cancer gave ipilimumab to 27 patients and not one tumour shrank by the standard measure, though one patient regressed later after apparent progression.
Adults with locally advanced or metastatic pancreatic adenocarcinoma, measurable disease, good performance status and minimal comorbidity received intravenous ipilimumab 3.0 mg/kg every 3 weeks, four doses per course, for up to two courses. Twenty-seven were enrolled (20 metastatic, 7 locally advanced), median age 55. Three had grade 3 or higher immune-mediated adverse events (colitis, encephalitis, hypophysitis). There were no responders by RECIST, although one subject had a delayed response after initial progression, with regression of the primary and 20 hepatic metastases and normalisation of tumour markers.
The first of the negative checkpoint trials that define pancreatic cancer as immunologically cold, with a single anecdote that kept the field going.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, CTLA-4, PD-1 / PD-L1 immune checkpoint & T-cell activation, Metastatic pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, CTLA-4, PD-1 / PD-L1 immune checkpoint & T-cell activation, Pancreatic ductal adenocarcinoma.
Shares CTLA-4, PD-1 / PD-L1 immune checkpoint & T-cell activation, Ipilimumab.
Shares Hot vs cold tumours, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma.